Open-Label Extensions The Key To Gantenerumab Success, Stresses Roche

Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.

Roche remains hopeful that its anti-Alzheimer's antibody gantenerumab can prevail where so many other amyloid-beta-targeting antibodies have failed. Aside from the failure of its own crenezumab, the most recent clinical disappointment was that of Biogen Inc./Eisai Co. Ltd.’s aducanumab, in March. (Also see "Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis" - Scrip, 22 March, 2019.)

“It is too early for us to draw concrete, scientific learnings from Biogen’s announcement,” Rachelle Doody, global head of neurodegeneration...